Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
Anticancer Research
|
January 30, 2026
Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy
Yasutaka Yamada, Tomoki Shirafuji, Kodai Sato, et al.
Journal of Cancer
|
October 2, 2023
Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study
Hirotoshi Iihara, Mototsugu Shimokawa, Hiroko Bando, et al.
Anticancer Research
|
May 27, 2026
Clinical Features and Prognostic Significance of Pulmonary Metastases in Metastatic Hormone-sensitive Prostate Cancer
Yasutaka Yamada, Marika Matsumoto, Mai Ikehara, et al.
The Prostate
|
March 31, 2026
A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer
Koichiro Kurokawa, Satoshi Yamamoto, Yasutaka Yamada, et al.
Japanese Journal of Clinical Oncology
|
May 17, 2025
Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center study
Yosuke Kinoshita, Yasutaka Yamada, Takuya Tsujino, et al.
BJU International
|
November 13, 2025
Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis
Tomoki Shirafuji, Yasutaka Yamada, Kodai Sato, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
Anticancer Research
|
January 30, 2026
Prolonged Castration Prior to Docetaxel Reduces Febrile Neutropenia in Patients With Metastatic Hormone-sensitive Prostate Cancer Receiving Triple Therapy
Yasutaka Yamada, Tomoki Shirafuji, Kodai Sato, et al.
Journal of Cancer
|
October 2, 2023
Doublet or Triplet Antiemetic Prophylaxis for Nausea and Vomiting Induced by Trastuzumab Deruxtecan: an Open-Label, Randomized, and Multicenter Exploratory Phase 2 Study
Hirotoshi Iihara, Mototsugu Shimokawa, Hiroko Bando, et al.
Anticancer Research
|
May 27, 2026
Clinical Features and Prognostic Significance of Pulmonary Metastases in Metastatic Hormone-sensitive Prostate Cancer
Yasutaka Yamada, Marika Matsumoto, Mai Ikehara, et al.
The Prostate
|
March 31, 2026
A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer
Koichiro Kurokawa, Satoshi Yamamoto, Yasutaka Yamada, et al.
Japanese Journal of Clinical Oncology
|
May 17, 2025
Clinical benefits of androgen receptor signaling inhibitors in patients with metastatic hormone-sensitive prostate cancer: real-world data from a multi-center study
Yosuke Kinoshita, Yasutaka Yamada, Takuya Tsujino, et al.
BJU International
|
November 13, 2025
Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis
Tomoki Shirafuji, Yasutaka Yamada, Kodai Sato, et al.
Page
of 2